These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 22681256)

  • 21. Pragmatic approaches to determine the exposures of drug metabolites in preclinical and clinical subjects in the MIST evaluation of the clinical development phase.
    Haglund J; Halldin MM; Brunnström A; Eklund G; Kautiainen A; Sandholm A; Iverson SL
    Chem Res Toxicol; 2014 Apr; 27(4):601-10. PubMed ID: 24593263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.
    Stepan AF; Walker DP; Bauman J; Price DA; Baillie TA; Kalgutkar AS; Aleo MD
    Chem Res Toxicol; 2011 Sep; 24(9):1345-410. PubMed ID: 21702456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development.
    Leclercq L; Cuyckens F; Mannens GS; de Vries R; Timmerman P; Evans DC
    Chem Res Toxicol; 2009 Feb; 22(2):280-93. PubMed ID: 19183054
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug metabolites in safety testing.
    Hastings KL; El-Hage J; Jacobs A; Leighton J; Morse D; Osterberg RE
    Toxicol Appl Pharmacol; 2003 Jul; 190(1):91-2;author reply 93-4. PubMed ID: 12831788
    [No Abstract]   [Full Text] [Related]  

  • 25. Fractional mass filtering as a means to assess circulating metabolites in early human clinical studies.
    Tiller PR; Yu S; Bateman KP; Castro-Perez J; McIntosh IS; Kuo Y; Baillie TA
    Rapid Commun Mass Spectrom; 2008 Nov; 22(22):3510-6. PubMed ID: 18853407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges and solutions to metabolites in safety testing: impact of the International Conference on Harmonization M3(R2) guidance.
    Yu H; Bischoff D; Tweedie D
    Expert Opin Drug Metab Toxicol; 2010 Dec; 6(12):1539-49. PubMed ID: 21067462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of volume of distribution at steady state in humans: comparison of different approaches.
    Zou P; Zheng N; Yang Y; Yu LX; Sun D
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):855-72. PubMed ID: 22591253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Streptomyces cytochromes P450: applications in drug metabolism.
    Lamb DC; Waterman MR; Zhao B
    Expert Opin Drug Metab Toxicol; 2013 Oct; 9(10):1279-94. PubMed ID: 23738914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards.
    Vishwanathan K; Babalola K; Wang J; Espina R; Yu L; Adedoyin A; Talaat R; Mutlib A; Scatina J
    Chem Res Toxicol; 2009 Feb; 22(2):311-22. PubMed ID: 19067650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idiosyncratic reactions and metabolism of sulfur-containing drugs.
    Zuniga FI; Loi D; Ling KH; Tang-Liu DD
    Expert Opin Drug Metab Toxicol; 2012 Apr; 8(4):467-85. PubMed ID: 22394356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Seeing through the mist: abundance versus percentage. Commentary on metabolites in safety testing.
    Smith DA; Obach RS
    Drug Metab Dispos; 2005 Oct; 33(10):1409-17. PubMed ID: 15985503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perspectives on non-clinical safety evaluation of drug metabolites through the JSOT workshop.
    Minagawa T; Nakano K; Furuta S; Iwasa T; Takekawa K; Minato K; Koga T; Sato T; Kawashima K; Kurahashi Y; Onodera H; Naito S; Nakamura K
    J Toxicol Sci; 2012; 37(4):667-73. PubMed ID: 22863847
    [TBL] [Abstract][Full Text] [Related]  

  • 33. From known knowns to known unknowns: predicting in vivo drug metabolites.
    Pelkonen O; Tolonen A; Korjamo T; Turpeinen M; Raunio H
    Bioanalysis; 2009 May; 1(2):393-414. PubMed ID: 21083174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum.
    Timmerman P; Anders Kall M; Gordon B; Laakso S; Freisleben A; Hucker R
    Bioanalysis; 2010 Jul; 2(7):1185-94. PubMed ID: 21083233
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are multimetabolite methods fit-for-purpose for supporting toxicology studies?
    Smith G
    Bioanalysis; 2011 Dec; 3(24):2701-4. PubMed ID: 22185267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Approaches to the assessment of stable and chemically reactive drug metabolites in early clinical trials.
    Baillie TA
    Chem Res Toxicol; 2009 Feb; 22(2):263-6. PubMed ID: 19216579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strategies for dealing with metabolite elucidation in drug discovery and development.
    Nassar AE; Talaat RE
    Drug Discov Today; 2004 Apr; 9(7):317-27. PubMed ID: 15037231
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meeting the demands of regulatory requirements: the significance of ADME.
    Guttendorf R
    Bioanalysis; 2012 Jun; 4(12):1395-7. PubMed ID: 22793021
    [No Abstract]   [Full Text] [Related]  

  • 39. Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?
    Penner N; Xu L; Prakash C
    Chem Res Toxicol; 2012 Mar; 25(3):513-31. PubMed ID: 22309195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Pharmacokinetic and metabolic studies in the development of drugs].
    Vereczkey L
    Acta Pharm Hung; 1995 Jul; 65(4):105-11. PubMed ID: 7572191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.